William Blair analyst Myles Minter has reiterated their bullish stance on IMUX stock, giving a Buy rating on December 31.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Myles Minter has given his Buy rating due to a combination of factors tied to Immunic’s lead asset and upcoming catalysts. He views vidofludimus calcium as a strong, next‑generation oral therapy for relapsing multiple sclerosis, with an added Nurr1 activation mechanism that could offer neuroprotective benefits beyond current DHODH inhibitors and potentially avoid liver safety burdens seen with teriflunomide. Despite the company’s relatively limited current cash position, he notes the availability of additional tranched capital and sees the funding constraint more as a timing and strategy issue than a fundamental weakness of the pipeline.
Minter also highlights the de-risking potential of the fully enrolled Phase III ENSURE trials in RMS, with data expected by the end of 2026, which he believes can act as a major value inflection point because the studies are placebo-controlled rather than head-to-head against teriflunomide. He considers a strategic partnership for vidofludimus in progressive MS, supported by encouraging CALLIPER trial data in non-active PMS, as a significant upside opportunity. In his view, recent challenges for competing BTK inhibitors, along with upcoming readouts from other oral MS agents, create an environment in which vidofludimus remains undervalued. Taken together, these clinical, competitive, and strategic considerations underpin his continued positive stance and Buy recommendation on Immunic’s stock.
Minter covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, VistaGen Therapeutics, and Intellia Therapeutics. According to TipRanks, Minter has an average return of 26.7% and a 57.77% success rate on recommended stocks.
In another report released on December 31, Chardan Capital also initiated coverage with a Buy rating on the stock with a $3.00 price target.